BioCina has completed the acquisition of an Adelaide, Australia, manufacturing facility from Hospira Adelaide Pty Ltd, an affiliate of Pfizer.
The leading contract development and manufacturing agency, BioCina, prioritizes the process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines, according to a press release from BioCina.
"Our vision is to be a trusted CDMO partner to the biopharma industry that helps save the lives of patients worldwide," BioCina CEO Ian Wisenberg said.
"We are now in full flight with unfettered ability to provide superior development and manufacturing services," Wisenberg said. "With the current global pandemic, we have seen the need to develop fast, innovative, life-saving medicines with world class science and superior quality to our partnered clients. This is at the core of the BioCina team's capability, experience and passion."
Wisenberg and Masood Tayebi, the company’s founder, plan to expand services to include the end-to-end manufacture of mRNA vaccines.
"BioCina has a strategic focus and significant investment in mRNA process development and manufacturing for vaccines and therapeutics to support solutions using this mRNA platform for our clients," Wisenberg said.